These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 21661186)

  • 1. [Thiazolidinediones].
    Nakamura T; Ueda Y
    Nihon Rinsho; 2010 Nov; 68 Suppl 9():476-80. PubMed ID: 21661186
    [No Abstract]   [Full Text] [Related]  

  • 2. Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies?
    Boulanger H; Mansouri R; Gautier JF; Glotz D
    Nephrol Dial Transplant; 2006 Oct; 21(10):2696-702. PubMed ID: 16880183
    [No Abstract]   [Full Text] [Related]  

  • 3. How about the effect of thiazolidinediones in diabetic nephropathy?
    Ina K
    Med Sci Monit; 2004 Jun; 10(6):LE7. PubMed ID: 15173677
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection.
    Panchapakesan U; Chen XM; Pollock CA
    Nat Clin Pract Nephrol; 2005 Nov; 1(1):33-43. PubMed ID: 16932362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].
    MMW Fortschr Med; 2007 Aug; 149(31-32):52-3. PubMed ID: 17849787
    [No Abstract]   [Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes.
    Setti G; Hayward A; Dessapt C; Barone F; Buckingham R; White K; Bilous R; Hiroshi K; Gruden G; Viberti G; Gnudi L
    Am J Nephrol; 2010; 32(5):393-402. PubMed ID: 20814199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Can glitazones provide protection of the kidneys?].
    Bonnet F
    Journ Annu Diabetol Hotel Dieu; 2007; ():77-84. PubMed ID: 18610759
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy.
    Agarwal R
    Am J Physiol Renal Physiol; 2006 Mar; 290(3):F600-5. PubMed ID: 16159895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in pathogenetic mechanisms of diabetic nephropathy.
    Nicholas SB
    Cell Mol Biol (Noisy-le-grand); 2003 Dec; 49(8):1319-25. PubMed ID: 14984004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms.
    Okada T; Wada J; Hida K; Eguchi J; Hashimoto I; Baba M; Yasuhara A; Shikata K; Makino H
    Diabetes; 2006 Jun; 55(6):1666-77. PubMed ID: 16731829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
    Ko GJ; Kang YS; Han SY; Lee MH; Song HK; Han KH; Kim HK; Han JY; Cha DR
    Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
    Katavetin P; Eiam-Ong S; Suwanwalaikorn S
    J Med Assoc Thai; 2006 Feb; 89(2):170-7. PubMed ID: 16579002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
    Calkin AC; Giunti S; Jandeleit-Dahm KA; Allen TJ; Cooper ME; Thomas MC
    Nephrol Dial Transplant; 2006 Sep; 21(9):2399-405. PubMed ID: 16720596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosiglitazone: opening Pandora's black box?
    Gilbert RE
    Clin J Am Soc Nephrol; 2007 Nov; 2(6):1329-31. PubMed ID: 17928463
    [No Abstract]   [Full Text] [Related]  

  • 16. The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy.
    Arora MK; Reddy K; Balakumar P
    Eur J Pharmacol; 2010 Jun; 636(1-3):137-44. PubMed ID: 20347778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone mitigates renal glomerular vascular changes in high-fat, high-calorie-induced type 2 diabetes mellitus.
    Rodriguez WE; Tyagi N; Joshua IG; Passmore JC; Fleming JT; Falcone JC; Tyagi SC
    Am J Physiol Renal Physiol; 2006 Sep; 291(3):F694-701. PubMed ID: 16609149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal moncyte chemoattractant protein-1 expression.
    Zheng M; Ye S; Zhai Z; Chen Y; Li X; Yang G; Fan A; Wang Y
    J Diabetes Complications; 2009; 23(2):124-9. PubMed ID: 18413206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection and dosing of medications for management of diabetes in patients with advanced kidney disease.
    Reilly JB; Berns JS
    Semin Dial; 2010; 23(2):163-8. PubMed ID: 20210915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chronic kidney disease and antidiabetic treatment].
    Berwert L; Teta D; Zanchi A
    Rev Med Suisse; 2007 Mar; 3(101):598-604. PubMed ID: 17436798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.